Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfs230D1M-EPA + AS01
- Development stage
- Phase 2
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pfs230D1M-EPA + AS01 is a transmission-blocking vaccine candidate against Plasmodium falciparum malaria. It consists of recombinant Pfs230 domain 1 (Pfs230D1M), a subdomain of a surface antigen found on gametocytes, gametes, and zygotes in the mosquito stage of Plasmodium falciparum. This antigen is conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA) and adjuvanted with AS01, a liposome-based adjuvant system containing the immune-enhancers MPL (3-O-desacyl-4'-monophosphoryl lipid A) and QS21 (a saponin molecule purified from the bark extract of Quillaja saponaria Molina tree). The vaccine is designed to interrupt malaria transmission by inducing antibodies that target the sexual stages of the parasite. When a mosquito takes a blood meal from a vaccinated individual, these antibodies prevent the parasite from developing in the mosquito, thereby blocking transmission to other humans.
- Other names
- Pfs230D1M-EPA conjugate vaccinePfs-230D1M-EPA conjugate vaccinePfs 230D1M-EPA conjugate vaccine
02
Targets
Pfs230D1 (Pfs230 domain 1)
Beyond the preview
Go deeper on Pfs230D1M-EPA + AS01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfs230D1M-EPA + AS01.